Aviva
BIO icon

Aviva’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aviva’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-796
Closed -$217K – 890
2024
Q2 		$217K Sell
796
-4
-0.5% -$1.16K ﹤0.01% 895
2024
Q1 		$277K Sell
800
-1,221
-60% -$402K ﹤0.01% 929
2023
Q4 		$653K Sell
2,021
-10,365
-84% -$3.25M ﹤0.01% 786
2023
Q3 		$4.44M Buy
12,386
+11,558
+1,396% +$4.46M 0.02% 525
2023
Q2 		$314K Hold
828
– – ﹤0.01% 924
2023
Q1 		$397K Sell
828
-2,082
-72% -$975K ﹤0.01% 948
2022
Q4 		$1.22M Sell
2,910
-51
-2% -$20.6K 0.01% 764
2022
Q3 		$1.24M Sell
2,961
-48
-2% -$23.9K 0.01% 892
2022
Q2 		$1.49M Sell
3,009
-2,222
-42% -$1.16M 0.01% 920
2022
Q1 		$2.95M Sell
5,231
-4,504
-46% -$2.72M 0.01% 703
2021
Q4 		$7.36M Buy
9,735
+1,138
+13% +$852K 0.03% 482
2021
Q3 		$6.41M Buy
8,597
+1,767
+26% +$1.32M 0.03% 508
2021
Q2 		$4.4M Sell
6,830
-2,341
-26% -$1.42M 0.02% 630
2021
Q1 		$5.24M Sell
9,171
-252
-3% -$149K 0.03% 528
2020
Q4 		$5.49M Sell
9,423
-1,471
-14% -$838K 0.03% 477
2020
Q3 		$5.62M Buy
10,894
+5,612
+106% +$2.84M 0.03% 421
2020
Q2 		$2.38M Sell
5,282
-5,534
-51% -$2.44M 0.01% 592
2020
Q1 		$3.79M Buy
10,816
+5,603
+107% +$2.06M 0.03% 494
2019
Q4 		$1.93M Buy
+5,213
New +$1.84M 0.01% 752

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aviva's BIO Position: Q3 2024 in Review

Aviva sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 796 shares — an estimated $217K sold.

Aviva first reported a position in BIO in Q4 2019 and held it in 19 quarters. The position peaked at $7.36M in Q4 2021. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Aviva reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Aviva sold 796 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $217K.
  • Aviva first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 19 quarters.
  • Aviva's Bio-Rad Laboratories Class A position peaked at $7.36M in Q4 2021.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Aviva's 13F filing for Q3 2024, filed 14 Nov 2024.